HEC ChangJiang Pharma (1558 HK): Finally a Vote, but the Offer Value Is Wrapped in Uncertainty
The vote is low-risk. However, the appraised value is a finger-in-the-sky valuation, and perplexingly, marginally increased despite the offeror's...
533 Views
China Healthcare Weekly (Oct.13)-Genor to Acquire Edding, RemeGen's Bleak Outlook, Zai Lab's Trouble
Genor/Edding are merging through a reverse takeover, but valuation is unsatisfactory. Remegen is negative example among China Biotech.Weak...
797 Views
UPDATE: China Medical System (CMS, 867 HK) – A Cheap Play on China’s Pending Health Care Crisis
A derating as a result of a transition period creates an excellent investment opportunity in a market that desperately needs to increase healthcare...
863 Views
China Medical System (CMS, 867 HK) – A Cheap Play on China’s Pending Health Care Crisis
A derating as a result of a transition period creates an excellent investment opportunity in a market that desperately needs to increase healthcare...
657 Views
HK CEO & Director Dealings (29 May 2024): J&T Global, Melco, Techtronic, Gushengtang, United Energy
The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flag those companies where...
472 Views